Black Diamond Therapeutics
BDTX
88 hedge funds and large institutions have $718M invested in Black Diamond Therapeutics in 2020 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 18 reducing their positions, and 11 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 18
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
10% more funds holding
Funds holding: 80 → 88 (+8)
1.75% more ownership
Funds ownership: 64.43% → 66.17% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
26% less capital invested
Capital invested by funds: $968M → $718M (-$249M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24M |
| 2 |
BlackRock
New York
|
+$10.5M |
| 3 |
DM
Deerfield Management
New York
|
+$8.11M |
| 4 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$5.83M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$44M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$16M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.53M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$4.51M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$3.48M |
BDTX Hedge Fund Activity: Q3 2020 in Review
88 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q3 2020, worth a combined $718M — down 26% from $968M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new BDTX positions and 11 closed out — a net gain of 8 holders — while 38 added to existing stakes and 18 trimmed.
The largest buyer was Vanguard Group, adding an estimated $24M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $44M sold.
- 88 institutional investors held Black Diamond Therapeutics (BDTX) as of Q3 2020, up from 80 in Q2 2020.
- Funds reported $718M of Black Diamond Therapeutics stock for Q3 2020, down 26% quarter-over-quarter.
- 19 funds opened new Black Diamond Therapeutics positions in Q3 2020 and 11 closed out, a net change of +8 holders.
- The largest Black Diamond Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $24M added.
- The largest Black Diamond Therapeutics seller in Q3 2020 was Perceptive Advisors, an estimated $44M sold.
Based on aggregated 13F filings for Q3 2020.